Showing results (41-50 of 154) with videos related to
Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.Pharmacotherapy|March 26, 2004
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virusPeter J Ruane, Gary J Richmond, Edwin DeJesus, et al.HIV Medicine|October 6, 2024
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysisJoseph J Eron, Moti Ramgopal, Olayemi Osiyemi, et al.HIV Clinical Trials|October 31, 2002
Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patientsMichael G Sension, Nicholaos C Bellos, Judy Johnson, et al.AIDS (London, England)|March 4, 2006
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresMargaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, et al.AIDS (London, England)|August 2, 2008
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North AmericaBenjamin Young, Kathleen Squires, Parul Patel, et al.HIV Clinical Trials|November 9, 2012
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudineKathleen E Squires, Benjamin Young, Edwin DeJesus, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2017
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected AdultsJoel E Gallant, Melanie Thompson, Edwin DeJesus, et al.Antimicrobial Agents and Chemotherapy|August 31, 2006
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjectsEdwin DeJesus, Peter J Piliero, Kim Summers, et al.HIV Clinical Trials|January 9, 2007
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot studyRichard Elion, Calvin Cohen, Edwin DeJesus, et al.Pageof 16